Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced results from 12 Phase 1 studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa® (patiromer) …
Yesterday was a great day for biotech stocks. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks 144 biotech and pharmaceutical companies, reversed losses and surged …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the company’s board of directors granted …
The New Year brings another turbulent season for biotech investors as top-line data continues to be released and the FDA’s approval process marches …
It may be a quiet week for analysts as the New Year approaches, but many are still eager to get their last ratings …
Relypsa Inc (NASDAQ:RLYP) is up nearly 6% to $29.40 in pre-market trading due to speculation that the company may be in M&A talks.
Chipotle Mexican Grill, Inc. (NYSE:CMG) is down 3.
Relypsa Inc (NASDAQ:RLYP) announced that Veltassa is launching in the U.S.
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, announced that VeltassaTM (patiromer) for oral suspension is now available for prescription to patients with hyperkalemia in …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced that on December 15, 2015, the compensation committee of the company’s board of directors granted …
